Business Context and Reporting Period
Company: Compass Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 22, 2022 (Event Date: August 1, 2022 for new agreement)
Business Context: The filing reports the entry into a new material definitive agreement for an at-the-market equity offering program and the termination of a prior similar agreement.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital market activities.
- Proposed Offering Size: Up to $75.0 million in aggregate offering price.
- Commission Rate: Up to 3% of gross proceeds paid to the sales agent.
- Legal Expense Reimbursement: Up to $75,000 for the sales agent's legal fees.
Material Changes
New Agreement (Item 1.01): On August 1, 2022, Compass entered into an Open Market Sale Agreement with Jefferies LLC. This agreement allows the company to sell shares of common stock through Jefferies as a sales agent or principal under an at-the-market offering program. The company is not obligated to sell any shares.
Termination of Prior Agreement (Item 1.02): On July 22, 2022, Compass agreed to terminate its previous At Market Issuance Sales Agreement with B. Riley Securities, Inc., effective July 29, 2022.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates the company has established a mechanism to raise capital up to $75.0 million at its sole discretion, subject to market conditions and customary parameters.
Risks and Contingencies:
- Dilution: The sale of shares under the new agreement will result in dilution to existing shareholders.
- Market Conditions: Sales are subject to the sales agent's normal trading practices and applicable laws; the company is not guaranteed to sell the full $75.0 million.
- Costs: The company incurs commissions and legal fees associated with the offering.
Investor Verification Checklist
- Verify the current share price and potential dilution impact of selling up to $75.0 million of stock.
- Confirm the effective date of the termination of the B. Riley agreement (July 29, 2022).
- Review the full text of the Open Market Sale Agreement (Exhibit 1.1) for specific termination rights and limitations.
- Check subsequent filings to determine if and when shares were actually sold under the Jefferies agreement.